多发性骨髓瘤后二次恶性瘤的风险:全国的病例控制队列研究
Heejoo Ko1, Seunghoon Han1, Sung-Soo Park2
1Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea.
Clinical lymphoma, myeloma & leukemia
|June 7, 2024
概括
多发性骨髓瘤幸存者面临更高的二次血液恶性瘤的风险,特别是与治疗相关的骨髓瘤. 非血液性恶性瘤的风险与一般人群相似.
科学领域:
- 在瘤学瘤学.
- 流行病学 流行病学
- 血液学 血液学 血液学
背景情况:
- 改善多发性骨髓瘤 (MM) 的存活率需要了解长期风险.
- 在MM幸存者中评估二次恶性瘤风险对于综合护理至关重要.
研究的目的:
- 将多发性骨髓瘤幸存者的二次恶性瘤风险与普通人群进行比较.
- 确定MM幸存者中高风险的特定类型的二次恶性瘤.
主要方法:
- 全国基于人口的病例控制队列研究,使用韩国国家健康保险服务 (KNHIS) 数据库 (2009-2020).
- 分析了7348名MM患者 (病例队列) 和29351名来自普通人口的匹配对照.
- 根据年龄,性别和并发症进行倾向性得分匹配.
主要成果:
- 在MM患者中,任何二次恶性瘤的累积发病率显著增加 (HR 1.576).
- 显著增加了血液恶性瘤的风险 (HR 8.026),特别是与治疗相关的髓状瘤 (t-MN) (HR 12.063).
- 在非血液性恶性瘤发病率上没有显著差异;可移植的MM患者表现出更高的二次恶性瘤风险.
结论:
- 毫毫米患者具有显著增加的血液恶性瘤的风险,特别是t-MN.
- 在MM幸存者中,非血液性恶性瘤风险似乎没有显著增加.
- 与lenalidomide前时代相比,lenalidomide时代的二次恶性瘤发病率没有显著增加.
相关概念视频
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Cancers Originate from Somatic Mutations in a Single Cell
11.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.9K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Bone Marrow Sampling and Transplants
324
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
324
Mismatch Repair
4.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.8K


